The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

The proposed UK assisted dying law may be delayed until 2029, raising doubts about its future. Novo Nordisk's shares tumble ...

Stock futures were lower on Wednesday, as investors weighed news on President Donald Trump's 25% tariff aimed at foreign cars ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Australians pay some of the lowest medicine prices in the world for a reason: our Pharmaceutical Benefits Scheme. Here’s how ...

Geology and tectonic evolution of the Archean North Pilbara Terrain, Pilbara Craton, Western Australia. Economic Geology ...